[Ischemic neuroretinopathy associated with use of interferon].
METHODS
A 46-year-old man, treated with peginterferon alpha 2-b and ribavirin for hepatitis C, experienced progressive painless blurring of vision in his left eye over a period of 4 days. Fundoscopy revealed pale temporal segmental edema of the optic disc and retina. Ocular examination and blood tests ruled out other disorders which could explain the visual disturbance.


CONCLUSIONS
The patient was diagnosed with an ischemic neuroretinopathy associated with interferon but, due to a favourable visual outcome, the treatment was not discontinued.
Miserachs-García
S
S
Servicio de Oftalmología, Hospital Universitari de Bellvitge, Barcelona, Spain. aquiles77@wanadoo.es
Mesa-Toledo
E
E
Arruga-Ginebreda
J
J
Castillo-Campillo
L
L
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018917:Optic Neuropathy, Ischemic / Q000139:chemically induced*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012164:Retinal Diseases / Q000139:chemically induced*; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014792:Visual Acuity / Q000187:drug effects; D058609:Visual Field Tests
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b